Chronic total occlusions in Sweden--a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
Evidence for the current guidelines for the treatment of patients with chronic total occlusions (CTO) in coronary arteries is limited. In this study we identified all CTO patients registered in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and studied the prevalence, patient char...
Saved in:
Published in | PloS one Vol. 9; no. 8; p. e103850 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
2014
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Evidence for the current guidelines for the treatment of patients with chronic total occlusions (CTO) in coronary arteries is limited. In this study we identified all CTO patients registered in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and studied the prevalence, patient characteristics and treatment decisions for CTO in Sweden.
Between January 2005 and January 2012, 276,931 procedures (coronary angiography or percutaneous coronary intervention) were performed in 215,836 patients registered in SCAAR. We identified all patients who had 100% luminal diameter stenosis known or assumed to be ≥ 3 months old. After exclusion of patients with previous coronary artery bypass graft (CABG) surgery or coronary occlusions due to acute coronary syndrome, we identified 16,818 CTO patients. A CTO was present in 10.9% of all coronary angiographies and in 16.0% of patients with coronary artery disease. The majority of CTO patients were treated conservatively and PCI of CTO accounted for only 5.8% of all PCI procedures. CTO patients with diabetes and multivessel disease were more likely to be referred to CABG.
CTO is a common finding in Swedish patients undergoing coronary angiography but the number of CTO procedures in Sweden is low. Patients with CTO are a high-risk subgroup of patients with coronary artery disease. SCAAR has the largest register of CTO patients and therefore may be valuable for studies of clinical importance of CTO and optimal treatment for CTO patients. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: Dr Stefan James has during the last 3 years received institutional research grants from Medtronic, Terumo Inc,Vascular Solutions and served as an advisory board member for Medtronic. Dr Jose P.S. Henriques has received unrestricted research grant from Abbott Vascular. Dr Elmir Omerovic serves as an advisory board member for Astra Zeneca and has received lecturing fees from Medtronic and Astra Zeneca. All other co-authors have no disclosures or potential conflicts of interest. Conceived and designed the experiments: TR EO LH JPSH CD DI JO OA UJ MA RJ SJ BL GO JH PA GM. Analyzed the data: TR EO LH JPSH CD DI JO OA UJ MA RJ SJ BL GO JH PA GM. Wrote the paper: TR EO LH JPSH CD DI JO OA UJ MA RJ SJ BL GO JH PA GM. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0103850 |